Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barohn

Showing results (251-260 of 345) with videos related to

Pageof 35
Sort By:
Annals of Neurology|April 27, 2005
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositisSteven A Greenberg, Jack L Pinkus, Geraldine S Pinkus, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 3, 2024
Measurement properties of the Inclusion Body Myositis Functional Rating ScaleSharfaraz Salam, Tara Symonds, Helen Doll, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 8, 2020
Primary lateral sclerosis: consensus diagnostic criteriaMartin R Turner, Richard J Barohn, Philippe Corcia, et al.
Neurology. Genetics|April 12, 2016
Phenotypic and molecular analyses of primary lateral sclerosisHiroshi Mitsumoto, Peter L Nagy, Chris Gennings, et al.
Trials|September 1, 2016
A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomizationAlexandra R Brown, Byron J Gajewski, Lauren S Aaronson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositisRohit Aggarwal, Andriy Bandos, Ann M Reed, et al.
Orphanet Journal of Rare Diseases|August 26, 2017
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseBarry J Byrne, Tarekegn Geberhiwot, Bruce A Barshop, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomolSharfaraz Salam, Jasper M Morrow, Michael P McDermott, et al.
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
JAMA Neurology|June 26, 2013
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trialRichard A Lewis, Michael P McDermott, David N Herrmann, et al.
Pageof 35

Showing results (251-260 of 345) with videos related to

Sort By:
Pageof 35
Annals of Neurology|April 27, 2005
Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositisSteven A Greenberg, Jack L Pinkus, Geraldine S Pinkus, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|July 3, 2024
Measurement properties of the Inclusion Body Myositis Functional Rating ScaleSharfaraz Salam, Tara Symonds, Helen Doll, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|February 8, 2020
Primary lateral sclerosis: consensus diagnostic criteriaMartin R Turner, Richard J Barohn, Philippe Corcia, et al.
Neurology. Genetics|April 12, 2016
Phenotypic and molecular analyses of primary lateral sclerosisHiroshi Mitsumoto, Peter L Nagy, Chris Gennings, et al.
Trials|September 1, 2016
A Bayesian comparative effectiveness trial in action: developing a platform for multisite study adaptive randomizationAlexandra R Brown, Byron J Gajewski, Lauren S Aaronson, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 28, 2014
Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositisRohit Aggarwal, Andriy Bandos, Ann M Reed, et al.
Orphanet Journal of Rare Diseases|August 26, 2017
A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe diseaseBarry J Byrne, Tarekegn Geberhiwot, Bruce A Barshop, et al.
Clinical and Experimental Rheumatology|February 28, 2025
Quantitative muscle magnetic resonance imaging as a biomarker for inclusion body myositis in clinical trials: exploring the in vivo effects of arimoclomolSharfaraz Salam, Jasper M Morrow, Michael P McDermott, et al.
Muscle & Nerve|March 21, 2013
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravisJames F Howard, Richard J Barohn, Gary R Cutter, et al.
JAMA Neurology|June 26, 2013
High-dosage ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A: results of a randomized, double-masked, controlled trialRichard A Lewis, Michael P McDermott, David N Herrmann, et al.
Pageof 35